Moxifloxacin for TB.
Moxifloxacin had activity similar to rifampin for the treatment of
pulmonary tuberculosis in a recent study and may have a place as part of
a short-course treatment regimen, said Dr. Roly D. Gosling of Royal-Free
and University College Medical School, London, and colleagues.
In 43 patients with pulmonary TB who were randomized to receive
treatment with isoniazid, moxifloxacin, or rifampin, the mean time to
kill 50% of bacilli was significantly different in the isoniazid group
(0.46 days) from both the moxifloxacin (0.88 days) and rifampin (0.71
days) groups, but did not differ significantly between the moxifloxacin
and rifampin groups. Early bactericidal activity (drop in sputum viable
count during the first 2 days of treatment) was greatest in the
isoniazid group (0.77 colony-forming units [cfu]/mL); this was
significantly greater than in the rifampin group (0.28 cfu/mL), but dial
not differ significantly from the 0.53 cfu/mL drop in the moxifloxacin
group (Am. J. Respir. Crit. Care Med.168:1342-45, 2003).